Vimarsana
Biggest News Aggregation in the World

Page 23 - Compugen Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Compugen Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Compugen Ltd Today - Breaking & Trending Today

Compugen's COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Anti-Tumor Activity and Immune Activation in Platinum Resistant Ovarian Cancer Patients - Vimarsana News

Compugen's COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Anti-Tumor Activity and Immune Activation in Platinum Resistant Ovarian Cancer Patients

At the time of abstract data cutoff, COM701+ nivolumab + BMS-986207 (anti-TIGIT) demonstrated encouraging 20% overall response rate and 40% disease control...

Compugen's COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Anti-Tumor Activity and Immune Activation in Platinum Resistant Ovarian Cancer Patients - Vimarsana News

Compugen's COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Anti-Tumor Activity and Immune Activation in Platinum Resistant Ovarian Cancer Patients

At the time of abstract data cutoff, COM701+ nivolumab + BMS-986207 demonstrated encouraging 20% overall response rate and 40% disease control rate in heavily pretreated patients with platinum...

Compugen to Participate in the JMP Securities Hematology and Oncology Summit - Vimarsana News

Compugen to Participate in the JMP Securities Hematology and Oncology Summit

/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today...

Compugen Reports Advancement Of AZD2936 Into Phase 2 By AstraZeneca; Triggers Milestone Payment - Vimarsana News

Compugen Reports Advancement Of AZD2936 Into Phase 2 By AstraZeneca; Triggers Milestone Payment

LONDON (dpa-AFX) - Compugen Ltd. (CGEN) said it expects to receive a milestone payment of $7.5 million from AstraZeneca, after AstraZeneca dosed the first patient in ARTEMIDE phase 2 study with

DelveInsight Highlights Major Advances, Transformative Therapies and 180+ Leading Players Wheeling the PD-1 and PD-L1 Inhibitors Pipeline Landscape - Vimarsana News

DelveInsight Highlights Major Advances, Transformative Therapies and 180+ Leading Players Wheeling the PD-1 and PD-L1 Inhibitors Pipeline Landscape

/PRNewswire/ -- DelveInsight's 'PD-1 and PD-L1 Inhibitors Competitive Landscape – 2022' report provides comprehensive global coverage of available, marketed,...